<DOC>
	<DOCNO>NCT02783170</DOCNO>
	<brief_summary>This pilot , prospective , randomize , open-label clinical trial . During study , pregnant woman randomize ( 1:1 ) receive co-administration single intramuscular ( IM ) 0.5 mL dose US-licensed inactivated influenza vaccine ( IIV ) single intramuscular ( IM ) 0.5 mL dose US-licensed Tetanus toxoid , reduce diphtheria toxoid acellular pertussis vaccine adsorb ( Tdap ) sequential administration vaccine ( IIV follow Tdap ~ 21 day later ) . Vaccines administer licensed study personnel . Prior Tdap/Td/TT influenza vaccine history verify medical record review possible . Injection-site ( local ) systemic reaction data assess vaccination day 7 day follow vaccination use either identical web-based paper diary , depend study participant preference . Maternal serum sample collect antibody titer relevant Tdap Influenza time point include : prior vaccination ( ) , ~21 day post vaccination ( ) , delivery . Additionally , cord blood serum analyze antibody titer . Pregnant woman follow comprehensive obstetric neonatal outcome obtain medical record review .</brief_summary>
	<brief_title>Safety Immunogenicity Simultaneous Tdap IIV Pregnant Women</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Pregnant , determine medical history ; 18 45 year age inclusive 2 . Intention receive Tdap IIV vaccine base Advisory Committee Immunization Practices ( ACIP ) recommendations 3 . Willing provide write informed consent prior initiation study procedures 4 . Singleton gestation ≥ 26 week 0 day gestation ≤32 week 0 day gestation time Visit 1 vaccination base reconciliation last menstrual period ultrasound date . Estimated due date ( EDD ) Gestational Age ( GA ) EDD base reconciliation `` sure '' first day last menstrual period ( LMP ) early date ultrasound . If LMP uncertain , early date ultrasound use determine EDD GA . If ultrasound derivedEDD agreement sureLMP derive EDD , LMPderived EDD use determine GA . If ultrasound derive EDD agreement LMPderived EDD , ultrasoundderived EDD use determine GA. 5 . English Spanish literate 6 . Intention available entire study period complete relevant study procedure , include followup phone call collection delivery information . 1 . IIV/LAIV receipt 20162017 influenza season prior study enrollment 2 . Tdap/Td/TT receipt current pregnancy prior study enrollment 3 . Has immunosuppression result underlie illness treatment , use anticancer chemotherapy radiation therapy within precede 36 month . 4 . Has active neoplastic disease ( exclude nonmelanoma skin cancer ) , history hematologic malignancy , current bleeding disorder , take anticoagulant ( daily low dose aspirin may acceptable ) . 5 . Has history receive immunoglobulin blood product ( exception Rhogam ) within 3 month prior enrollment study . 6 . Known preexist diabetes mellitus autoimmune disorder . 7 . Febrile illness within last 24 hour oral temperature &gt; /= 100.4°F ( &gt; /= 38.0°C ) prior IIV Tdap administration 8 . Contraindication IIV receipt include history severe allergic reaction previous dose influenza vaccine ; vaccine component , include egg protein 9 . Contraindication Tdap receipt include history severe allergic reaction previous dose tetanus toxoid , diphtheria toxoid , pertussis antigencontaining vaccine encephalopathy within 7 day administration previous dose pertussis antigencontaining vaccine attributable another identifiable cause 10 . Arthustype hypersensitivity reaction follow prior dose tetanus toxoidcontaining vaccine within last 10 year 11 . Any condition may interfere assessment local injection site reaction , e.g . lymphadenectomy obscure tattoos 12 . History GuillainBarré syndrome within 6 week prior dose tetanus toxoid , diphtheria toxoid pertussis antigencontaining vaccine influenza vaccine 13 . Known suspected impairment immunologic function include infection HIV , hepatitis B C 14 . Use immunosuppressive cytotoxic drug except receipt oral parenteral ( intravenous , subcutaneous intramuscular ) corticosteroids 30 day prior enrollment . Persons use oral parenteral corticosteroid within 12 month prior enrollment may enrol long course therapy le 14 consecutive day dose give within 30 day enrollment . Intraarticular , bursal , tendon , epidural injection corticosteroid permissible recent injection 30 day prior enrolment . Persons apply topically corticosteroid either upper arm ( i.e . injection site ) may enrol 1 day therapy complete . Corticosteroids administer topically noninjection site , inhalation intranasally permissible 15 . Receipt license vaccine within 14 day prior study vaccination planning receipt vaccine ( except study vaccine ) prior Visit 7 follow . 16 . Receipt live vaccine current pregnancy . 17 . High risk preterm birth ( active preterm labor , short cervix , cervical cerclage , receipt antenatal corticosteroid fetal lung maturity prior Visit 1 ) 18 . Antenatal ultrasound diagnosis fetal growth restriction , define &lt; 10th percentile estimate fetal weight gestational age 19 . Known fetal congenital anomaly , e.g . genetic abnormality malformation base antenatal ultrasound 20 . Any condition , opinion investigator , may pose health risk subject interfere evaluation study objective . 21 . Anyone relative research study personnel 22 . Anyone employee research study personnel 23 . Anyone already enrol plan enroll another clinical trial investigational product . Coenrollment observational behavioral intervention study allow time .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Tdap vaccine</keyword>
	<keyword>Flu vaccine</keyword>
	<keyword>vaccine pregnancy</keyword>
	<keyword>immunization pregnancy</keyword>
	<keyword>Whooping Cough</keyword>
	<keyword>Pertussis</keyword>
	<keyword>Influenza</keyword>
</DOC>